• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Research and Markets: Drug Discovery Efforts for the Most Prevalent Central Nervous System Diseases Meeting With Varied Success

Posted on: Friday, 11 March 2005, 06:00 CST

DUBLIN, Ireland, March 11 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/reports/c13823) has announced the addition of Neurogenomics and Neurotherapeutic Strategies: New Directions in Platforms, Targets, and Therapeutic Approaches to their offering.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH )

CNS disorders affect a vast patient population and represent a huge area of unmet therapeutic need. In the United States alone, Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) afflict more than 6.5 million people. Drug discovery efforts for the most prevalent CNS diseases have met with varying success; it is estimated that billions of dollars are spent every year on prescription drug sales; however, many current therapies merely treat the symptoms but do not provide cures.

The complexities of CNS diseases make this area a challenging but potentially very rewarding area for research. Neurogenomics and Neurotherapeutic Strategies: New Directions in Platforms, Targets, and Therapeutic Approaches evaluates drug development efforts in six major CNS diseases:

-- Alzheimer's disease

-- Parkinson's disease

-- Amyotrophic Lateral Sclerosis

-- Schizophrenia

-- Depression

-- Bipolar disorder

This report surveys the numerous R&D efforts under way at companies and institutions around the world, focusing on discovery projects, preclinical studies, and early-stage human trials. It also addresses investigational methods, proposed mechanisms of action, pathways, and targets that research teams are exploring in order to move one step closer to developing effective therapeutics. Novel tools and platforms, including animal models, molecular imaging, and biomarkers, will also be covered.

Companies and Organizations Featured in Report

Forest Laboratories

Boehringer-Ingelheim Pharmaceuticals

Prana Biotechnology

Memory Pharmaceuticals

GlaxoSmithKline

Acumen Pharmaceuticals

Bristol-Myers Squibb

Ceregene

NPS Pharmaceuticals

Targacept

Cortex Pharmaceuticals

Neurocrine Biosciences

Neurochem

Lexicon Genetics

Avigen

Neurologix

CytRx

Cephalon

Newron Pharmaceuticals

deCODE genetics

Acadia Pharmaceuticals

Prana Biotechnology

Pherin Pharmaceuticals

Targacept

Wyeth

GlaxoSmithKline

Pfizer

Sanofi-Synthélabo

AstraZeneca

Aventis Pharmaceuticals

Eli Lilly

Lexicon Genetics

Somerset Pharmaceuticals

Potomac Pharma and the Stanley Medical Research Institute

NPS Pharmaceuticals

American Biogenetic Sciences

Baylor College of Medicine's

Harvard Medical School's

Johns Hopkins University's

University of California

For more information visit http://www.researchandmarkets.com/reports/c13823

Laura Wood

Senior Manager

Research and Markets

press@researchandmarkets.com

Fax: +353 1 4100 980

Photo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH

Research and Markets

CONTACT: Laura Wood, Senior Manager of Research and Markets,press@researchandmarkets.com, Fax, +353-1-4100-980

Web site: http://www.researchandmarkets.com/reports/c13823

Source: PRNewswire

More News in this Category